MTAA Welcomes Sue Martin As New Board Chair
The Medical Technology Association of Australia (MTAA) has today welcomed the appointment of its new chair, Sue Martin, of Johnson & Johnson MedTech Australia and New Zealand, and thanked outgoing chair, Maurice Ben-Mayor, of Stryker South Pacific.
After four years leading Australia’s MedTech industry through countless reforms, a once in a century pandemic and a change of federal government, Mr Ben-Mayor leaves with a strong record of accomplishments under his chairmanship.
Speaking on his time as chair, Mr Ben-Mayor said he was proud of the work MTAA has been able to achieve over the past four years, by working together as an industry and in collaboration with government and other private health stakeholders.
“Thanks to the hard work of our members and, particularly our Board and committees, we were able to secure workable reforms to the Prostheses List, lead the industry’s step-up to support government’s nation-wide response to the pandemic by securing vital supplies and medical equipment, and work closely with the Therapeutic Goods Administration on regulatory reforms remaining strong advocates of fit-for-purpose policies,” Mr Ben-Mayor said.
“I’m excited to hand the baton over to Sue Martin as she takes our industry forward from strength to strength. Sue is a powerful voice for MedTech and thoughtful leader best suited to take the industry into its next chapter.”
Having served as the Vice Chair of MTAA’s Board since 2019 and a member of the Board since 2018, Sue Martin, comes to the role of chair with a strong track record and history working in MedTech and across the health sector.
Since January 2018, Sue has been managing director for Johnson & Johnson MedTech Australia and New Zealand. She is responsible for the company’s entire Medical Devices portfolio in ANZ, including orthopaedics, general and speciality surgery, cardiovascular, and reconstructive surgery products.
“I want to thank Maurice for his pragmatic, determined and engaging leadership of the industry and of MTAA’s Board. He has played an instrumental role in leading our industry through a tumultuous period in our history, and through the challenges and opportunities of ongoing reforms,” Ms Martin said.
“I’m looking forward to hitting the ground running as we drive forward with a number of vital strategic priorities for MTAA, determined by the Board, and developed by MTAA’s Public Affairs Committee (PAC), while I served as chair of the PAC.
“MTAA’s current industry-wide analysis being undertaken on the Value of MedTech, launching next year, and the more targeted report on opportunities for Australia through investment and adoption of a connected health future, are just two of immediate priorities that I look forward to delivering early next year.
“MTAA enjoys strong industry and medical partnerships that help us in supporting both innovative MedTech start-ups in Australia, access to new and better technologies, and promoting improved patient outcomes. Those serve as the basis of everything we do.”
MTAA CEO, Ian Burgess, thanked Mr Ben-Mayor for his tremendous service to the association and the wider MedTech industry, and welcomed Ms Martin as MTAA’s new chair.
“I am thrilled to have someone with Sue’s knowledge, expertise and dynamism stepping into the role of chair of MTAA’s Board. As a highly respected leader in our industry, Sue brings with her more than 20 years of experience, having worked across multiple countries and functions, spanning marketing and sales, to general management,” Mr Burgess said.
“As CEO, I’m looking forward to continuing to work closely with Sue to advance the strategic priorities of our industry and the Board’s vision for the future. I’d also like to take a moment to thank Maurice for his outstanding service to MTAA and the wider MedTech community.
“Maurice’s steadfastness and determined perseverance has seen MTAA, and MedTech in Australia, come out of some of the most challenging economic times we’ve seen in 100 years, a stronger voice to shape the direction of Australia’s health system for the betterment of patients.”
